| Literature DB >> 25043675 |
Adriana Zingone1, Weixin Wang2, Meghan Corrigan-Cummins2, S Peter Wu1, Ryan Plyler2, Neha Korde1, Mary Kwok1, Elisabet E Manasanch1, Nishant Tageja1, Manisha Bhutani1, Marcia Mulquin1, Diamond Zuchlinski1, Mary Ann Yancey1, Mark Roschewski1, Yong Zhang3, Aldo M Roccaro3, Irene M Ghobrial3, Katherine R Calvo2, Ola Landgren4.
Abstract
Currently, no reliable biomarkers are available to predict transformation from smoldering myeloma (SMM) to multiple myeloma (MM). Using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) we assessed the levels of a broad range of cytokines and chemokines in the peripheral blood (PB) and bone marrow (BM) supernatant collected from 14 SMM and 38 MM patients and compared to healthy donors. We found significantly increased levels of key cytokines, in particular CXCL8 (IL-8), associated with progressive disease state (controls→SMM→MM). Cytokine profiles were found similar in PB and BM. Five of fourteen SMM patients (36%) progressed to MM. Our findings, although based on a limited number of patients, suggest that serum-based cytokines may have a future role as biomarkers for disease progression and could potentially be assessed as novel targets for treatment. Published by Elsevier Ltd.Entities:
Keywords: CXCL8; Chemokines; Multiple myeloma
Mesh：
Substances：
Year: 2014 PMID： 25043675 PMCID： PMC4148078 DOI： 10.1016/j.cyto.2014.05.017
Source DB: PubMed Journal: Cytokine ISSN： 1043-4666 Impact factor: 3.861